Lower vasopressin

The principal hormones of the human posterior pituitary include the two nonapeptides, oxytocin [50-56-6] and arginine vasopressin [11000-17-2] (antidiuretic hormone, ADH). Many other hormones, including opioid peptides (see Opioids, endogenous), cholecystokinin [9011-97-6] (CCK) (see Hormones, BRAIN oligopeptides), and gastrointestinal peptides, also have been located in mammalian neurohypophysis (6), but are usually found in much lower concentrations (7). Studies have demonstrated that oxytocin and vasopressin are synthesized in other human organs, both centrally and peripherally, and there is considerable evidence for their role as neurotransmitters (see Neuroregulators) (8). 

Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are members of a family of so-called natriuretic peptides, synthesized predominantly in the cardiac atrium, ventricle, and vascular endothelial cells, respectively (G13, Y2). ANP is a 28-amino-acid polypeptide hormone released into the circulation in response to atrial stretch (L3). ANP acts (Fig. 8) on the kidney to increase sodium excretion and glomerular filtration rate (GFR), to antagonize renal vasoconstriction, and to inhibit renin secretion (Ml). In the cardiovascular system, ANP antagonizes vasoconstriction and shifts fluid from the intravascular to the interstitial compartment (G14). In the adrenal cortex, ANP is a powerful inhibitor of aldosterone synthesis (E6, N3). At the hypothalamic level, ANP inhibits vasopressin secretion (S3). It has been shown that some of the effects of ANP are mediated via a newly discovered hormone, called adreno-medullin, controlling fluid and electrolyte homeostasis (S8). The diuretic and blood pressure-lowering effect of ANP may be partially due to adrenomedullin (V5). 

Neurohypophysis. Release of vasopressin (antidiuretic hormone) results in lowered urinary output (p. 164). Levels of vasopressin necessary for vasoconstriction will rarely be produced by nicotine. 

The use of vasopressin and terlipressin for the management of septic shock has been reviewed a maximum dose of 0.04 U/minute is recommended (5). Vasopressin 0.23 U/minute in patients with hepatorenal syndrome did not appear to be associated with the adverse effects that occur at the lower doses that are used to treat other critically ill patients (6). 

When arginine vasopressin is used in high single doses (4—16 IU), to control upper gastrointestinal tract bleeding, gut ischemia has been reported (20). Continuous infusions at lower doses have shown changes suggestive of splanchnic hypoperfusion. 

VIP is a neurotransmitter in the cerebral cortex, the hypothalamus, amygdala, hippocampus, corpus striatum, and the vagal nuclei of the medulla oblongata (131,132). VIP receptors are widely distributed in cerebral cortex, amygdaloid nuclei, hippocampus, olfactory lobes, thalamus, and the suprachias-matic nucleus, and are present in lower concentrations in the hippocampus, brainstem, spinal cord, and dorsal root ganglia. VIP is also involved in the release of other hormones such as CRH, PRL, oxytocin, and vasopressin. 

Despite this increase in fear-related behavior, the 5-HT3A-R KO mice actually display decreased ACTH release in response to restraint stress or lipopolysac-charide (LPS) injection, although the KOs did not differ from controls in their CRH expression or sensitivity to CRH (140). This decrease in stress-induced ACTH release might thus result from lower arginine vasopressin (AVP) mRNA expression in the paraventricular nucleus (PVN) of 5-HT3A-R KO mice (140), as AVP release in the PVN potentiates CRF-induced ACTH release (144). 

Poly(amino acid)s (PAAs) have also been used in drug delivery PEO-(l-aspartic acid) block copolymer nano-associates , formed by dialysis from a dimethyl acetamide solution against water, could be loaded with vasopressin. PLA-(L-lysine) block copolymer microcapsules loaded with fluorescently labelled (FITC) dextran showed release profiles dependent on amino acid content. In a nice study, poly(glutamate(OMe)-sarcosine) block copolymer particles were surface-grafted with poly(A-isopropyl acrylamide) (PNIPAAm) to produce a thermally responsive delivery system FITC-dextran release was faster below the lower critical solution temperature (LCST) than above it. PAAs are prepared by ring-opening polymerisation of A-carboxyanhydride amino acid derivatives, as shown in Scheme 1. 

Terlipressin has similar, but less pronounced, systemic hemodynamic effects to vasopressin, including increases in mean arterial pressure and reduced heart rate (6). Of 105 patients who had continuous terlipressin infusions for variceal bleeding in a multicenter study, lower limb ischemia developed in two and cardiac ischemia in one (7). 

In the toad urinary bladder, an experimental model of the mammalian collecting tubule, addition of hthium to the mucosal surface (but not to the serosal surface) markedly inhibited both basal and arginine vasopressin-stimulated water flow [50]. The concentration of mucosal lithium used in these studies (10 mEq/L) was comparable to or even lower than that usually found in the urine of patients on well-controlled lithium therapy (that is, 10 to 40 mEq/L) [63] Fernandez et al. [53] confirmed the inhibitory effect of lithium on water flow in toad urinary bladders exposed only submaximal concentrations of arginine vasopressin. Inhibition of cyclic adenosine monophosphate-stimulated water flow when lithium (2 mEq/L) was applied to the serosal surface of the toad bladder was reported in one study. Such an effect of lithium, when applied to the serosal surface has, to our knowledge, not been found by any other investigators. As herein discussed, the bulk of evidence supports the notion that the action of lithium on water transport is the result of its cell uptake from the luminal (apical) surface of the collecting tubule. 

Felypressin. Felypressin. 2-L-phenylalunine-il-t.-lysine vasopressin, has relatively low antidiuretic activity and little oxytocic activity. It has considerable pressor (i.c., vasoconstrictor) activity, which differs from that of epinephrine (i.e., following capillary con.striclion in the intestine it lowers the pressure in the vena portae, whereas epinephrine rai.ses the portal pre.ssiire). Felypressin al.so cau.ses increased renal blood flow in the cal. whereas epinephrine brings about a fall In renal bltxal How. Felypressin is 5 time.s more effective as a va.sopre.ssor than is lysine vasopressin and is recommended in surgery to minimi/.e blood How, especially in obstetrics and gynecology. 

Several animal studies have demonstrated the beneficial effect of vasopressin on coronary and cerebral blood flow. Although vasopressin improves vital organ perfusion during VF, myocardial oxygen consumption is lower with vasopressin than with epinephrine. Vasopressin also may have a beneficial effect on renal blood flow by stimulating V2 receptors in the kidney, causing vasodilation and increased water reabsorption. With regard to splanchnic blood flow, however, most studies have shown that vasopressin has a detrimental effect compared with epinephrine. ... 

---